Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. (SEER) is a pioneering life sciences company advancing proteomic research through its innovative Proteograph Product Suite. This page aggregates official news and developments related to the company's transformative nanoparticle technology, strategic partnerships, and research breakthroughs.
Investors and researchers will find timely updates including earnings reports, product innovations, and scientific collaborations. Our curated collection features press releases on financial results, technology validations, and operational milestones that demonstrate SEER's leadership in unbiased proteomic analysis.
The news hub covers essential developments across three key areas: financial performance updates, advancements in multi-omics research capabilities, and strategic alliances with biopharma partners. Users can track how SEER's automated workflows and engineered nanoparticles continue to redefine large-scale protein studies.
Bookmark this page for centralized access to SEER's latest progress in enabling deep biological insights through proteomics. Check regularly for updates on how the company's integrated platform supports biomarker discovery and accelerates research across academic and commercial laboratories.
Seer has published three papers demonstrating its Proteograph Product Suite's ability to uncover novel plasma proteomic insights during spaceflight. Data from the SpaceX Inspiration4 mission revealed acute changes in oxidative stress, brain homeostasis, and coagulation, with many alterations persisting six months post-flight. Seer’s technology allows comprehensive profiling of astronauts' physiological responses, aiding precision medicine and biomarker discovery. The studies include a substantial dataset from multiple space missions and highlight the Proteograph XT Assay Kit’s capabilities in detecting over 60,000 peptides and 8,000 proteins in plasma samples.
Seer has announced the completion of a groundbreaking mass spectrometry study by PrognomiQ, utilizing Seer's Proteograph Product Suite and the Thermo Scientific Orbitrap Astral mass spectrometer. This multi-cancer case-control study involved 2,840 subjects and identified over 13,000 protein groups, with an average of 8,200 protein groups per sample. The study, conducted across 77 clinical sites in the U.S., showcases the combined power of Seer and Thermo Fisher's technologies in early cancer detection. The findings will be presented at the ASMS Conference on June 6.
Seer, Inc. (Nasdaq: SEER), a life sciences company, reported Q1 2024 financial results. Achieved $3.1M in revenue, expanded STAC program to Europe, validated Proteograph Product Suite, launched Insights Grant Program, authorized $25M share repurchase program. Experienced a 24% revenue decrease primarily from product and related party revenue. Operating expenses decreased by 10%. Net loss was $20.7M. Cash position at $359.2M. Board authorized $25M share repurchase program. Full year revenue guidance for 2024 is $16-18M.
Seer, Inc. (Nasdaq: SEER) has launched a new Seer Technology Access Center in Bonn, Germany, to provide European life sciences researchers with access to the Seer Proteograph™ Product Suite and mass spectrometry technologies. The facility aims to support unbiased proteomic studies, accelerate biomarker discovery, and drug development. The European STAC will offer programs to enhance the availability of state-of-the-art proteomics technologies and assist researchers in expanding their research scope.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
